

P40 antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP22458a

Product Information

Application	WB, E
Primary Accession	Q9H3D4
Reactivity	Human
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit Ig
Clone Names	R02976
Calculated MW	76785

Additional Information

Gene ID	8626
Other Names	Tumor protein 63, p63, Chronic ulcerative stomatitis protein, CUSP, Keratinocyte transcription factor KET, Transformation-related protein 63, TP63, Tumor protein p73-like, p73L, p40, p51, TP63, KET, P63, P73H, P73L, TP73L
Target/Specificity	This antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between amino acids from human.
Dilution	WB~~1:2000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	P40 antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TP63
Synonyms	KET, P63, P73H, P73L, TP73L
Function	Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and

auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.

Cellular Location

Nucleus

Tissue Location

Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues


Background

Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.

References

Senoo M.,et al.Biochem. Biophys. Res. Commun. 248:603-607(1998).
Augustin M.,et al.Mamm. Genome 9:899-902(1998).
Yang A.,et al.Mol. Cell 2:305-316(1998).
Osada M.,et al.Nat. Med. 4:839-843(1998).
Hagiwara K.,et al.Cancer Res. 59:4165-4169(1999).

Images



All lanes: Anti-P40 antibody at 1:2000 dilution Lane 1: HL-60 whole cell lysate Lane 2: THP-1 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 40 KDa Blocking/Dilution buffer: 5% NFDm/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.